Pricing & Access· August 8, 2026 · 14 min read
Novo Nordisk portfolio dossier (Q2 2026): Wegovy, CagriSema & obesity pipeline
By Ran Chen#Novo Nordisk#Semaglutide#Wegovy
Topic
Semaglutide
Semaglutide GLP-1 receptor agonist clinical data, Orange Book patent landscape, oral versus injectable formulations, and loss of exclusivity.